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ABSTRACT
Antisense oligonucleotides (ASOs) modulate cellu-
lar target gene expression through direct binding
to complementary RNA. Advances in ASO chem-
istry have led to the development of phosphoroth-
ioate (PS) ASOs with constrained-ethyl modifications
(cEt). These next-generation cEt-ASOs can enter
cells without transfection reagents. Factors involved
in intracellular uptake and trafficking of cEt-ASOs
leading to successful target knockdown are highly
complex and not yet fully understood. AZD4785 is
a potent and selective therapeutic KRAS cEt-ASO
currently under clinical development for the treat-
ment of cancer. Therefore, we used this to inves-
tigate mechanisms of cEt-ASO trafficking across a
panel of cancer cells. We found that the extent of
ASO-mediated KRAS mRNA knockdown varied sig-
nificantly between cells and that this did not corre-
late with bulk levels of intracellular accumulation. We
showed that in cells with good productive uptake,
distribution of ASO was perinuclear and in those
with poor productive uptake distribution was periph-
eral. Furthermore, ASO rapidly trafficked to the late
endosome/lysosome in poor productive uptake cells
compared to those with more robust knockdown. An
siRNA screen identified several factors mechanisti-
cally involved in productive ASO uptake, including
the endosomal GTPase Rab5C. This work provides
novel insights into the trafficking of cEt-ASOs and
mechanisms that may determine their cellular fate.
INTRODUCTION
Antisense oligonucleotides (ASOs) are single-stranded
DNA/RNA-like molecules that can be used as biological
tools to modulate the expression of specific cellular tar-
get RNA.ASOs function throughWatson–Crick hybridiza-
tion, directly binding to complementary RNA sequences
andmodulating function. This is done through a number of
different mechanisms, including recruitment of the enzyme
Ribonuclease H (RNase H) that cleaves the RNA/ASO du-
plex leading to the down-regulation of target mRNA and
protein (1,2). As ASOs are designed solely based on gene
sequences they can be utilized to develop a wide range of
inhibitors including those against previously ‘undruggable
proteins’ that are difficult to target by classical therapeu-
tic approaches. Recent progress in ASO chemistry has en-
abled the advancement of therapeutic ASOs with drug-like
properties (3,4). These next-generationASOs have chemical
modifications including a phosporothioate (PS) backbone
and 2′-4′constrained ethyl chemistry (cEt) at either end of
the molecule. These modifications improve the potency of
cEt-ASOs compared to the 2′-O-methoxyethyl (2′-MOE)
oligonucleotides, and a number of cEt-ASOs are currently
being developed in several disease areas including cancer
(5–8).
cEt-ASOs are able to enter cells without the need of
a delivery reagent in a process termed ‘free uptake’ that
is mediated through context-dependent endocytic mecha-
nisms (9–11). Pathways of ASO uptake resulting in target
engagement are considered ‘productive’; however to date
mechanisms of productive trafficking of ASOs have not
been fully elucidated (12,13). ASO cellular internalization
is known to be dependent on ASO binding with membrane-
associated or extracellular proteins. Recent studies using
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2′MOE-ASOs have begun to characterize cellular internal-
ization mechanisms that may be important for productive
uptake. For example, in mouse hepatic cells, uptake appears
to be through a clathrin-independent but Adaptor-Related
Protein Complex 2 Mu 1 Subunit (AP2M1)-dependent
mechanism (14). Others have shown that Stabilin recep-
tors bind ASOs with high affinity, and are responsible for
bulk, clathrin-mediated endocytosis in mouse and rat liver
cells (15). Another recent study in A431 cells showed that
epidermal growth factor receptor (EGFR) binds ASOs at
the cell surface and is important for productive ASO up-
take through trafficking from early to late endosomes and
may possibly contribute to the release of PS-ASOs from
late endosomes (16). Once internalized, the ASO enters the
endocytic network and is reported to distribute to early
and late endosomes and also lysosomes (17). Escape from
membrane-bound organelles is also considered to be im-
portant for the ASOs to engage with target mRNA and
mediate a functional effect. Wang et al. characterized the
importance of Annexin A2 (ANAX2) in facilitating endo-
cytic trafficking of PS-ASOs modified with 2′-MOE chem-
istry, leading to target engagement and knockdown inHeLa
and A431 human cell lines as well as mouse MHT cells
via the release of ASOs from late endosomal compartments
(18). Other data have shown that lysobisphosphatidic acid
(LBPA) is required for the release of 2′MOEASOs from the
late endosome and subsequent activity on its mRNA target
in the cell (19). Interestingly, across a panel of cell lines, the
IC50 of target knockdown with an ASO applied without a
delivery reagent can differ dramatically, which is likely due
to differences in cellular uptake and trafficking of the ASO
molecules. The mechanisms that mediate intracellular up-
take that leads to productive target engagement by ASOs
are clearly complex and, despite recent advances in the field,
are not yet fully understood.
To date there have been no studies to characterize traf-
ficking of cEt-ASOs within the cell and limited in vitro
studies across ASO molecules in clinically relevant mod-
els. AZD4785, a potent and selective KRAS therapeutic
cEt-ASO, is currently being developed to treat KRAS-
dependent tumours. It is a 16-nt chimeric gapmer ASO
that has PS linkages throughout the molecule and at ei-
ther end has three nucleotides containing cEtmodifications.
AZD4785 binds to the 3′UTR of KRAS mRNA leading to
the down-regulation of mRNA and protein and subsequent
inhibition of downstream Ras effector pathways and prolif-
eration inKRAS-mutant cells (20). AZD4785was identified
as a lead compound out of 2160 ASOs and was selected
based on its activity in cells and xenograft models; sys-
temic delivery of AZD4785 to mice bearing KRAS-mutant
NSCLC xenografts or patient-derived xenografts resulted
in inhibition of KRAS tumour expression and subsequent
anti-tumour activity (20).
In this work, we sought to characterize pathways of cEt-
ASO trafficking using AZD4785 across a panel of tumour
cell lines with different levels of productive ASO uptake
to provide a comprehensive overview of uptake and intra-
cellular trafficking across clinically relevant cancer models.
Understanding these mechanisms in relevant models could
enable patient selection strategies and identify those most
likely to benefit from cEt-ASO therapies. Furthermore, es-
tablishing relevant mechanistic pathways will enable identi-
fication of novel chemical, delivery and combination strate-
gies to improve ASO productive uptake, reduce doses and
cost of goods and increase translation to the clinic. Findings
from our work highlight key cEt-ASO trafficking mecha-
nisms, such as non-productive delivery to the late endo-
some, and influence of proteins including the endosomal
Rab GTPase Rab5C that plays a crucial role in productive
ASO trafficking within the cell.
MATERIALS AND METHODS
Cell lines and ASOs
MiaPaca-2, BxPC3, Panc 10.05, Colo-205, SW837, SW620,
HT-29, NCI-H460, NCI-H1437, NCI-H358, A549, NCI-
H2030, Calu-6, A427 and LK2 cell lines were from ATCC,
PC9were obtained fromECACC.All cell lines were authen-
ticated by short tandem repeat (STR) analysis. Cells were
cultured in RPMI media (Sigma) plus 10% foetal bovine
serum (FBS). The antisense oligonucleotides used in this
study were synthesized as described previously (4). The
sequences of the ASOs used are AZD4785/Ionis 651987
GCTATTAGGAGTCTTT, Ionis 746275 TCTTGATTTG
TCAGCA and Ionis 549148 GGCTACTACGCCGTCA.
The letters indicate DNA, underlined letters indicate cEt
modified bases and the italicized letters indicate MOE
bases.
ASO treatment
Cells between 20% and 50% confluency (depending on the
timeframe of the assay) were dosed with ASOs 24 h after
seeding. For cell dosing, ASOs were diluted in phosphate-
buffered saline (PBS) before being administered to cells.
Cells were then incubated at 37◦C, 5% CO2 for the duration
of the assay.
RNA preparation, quantitative real-time PCR (RT-qPCR)
and analysis
Total RNA was prepared from cells grown in 384-well
plates or 96-well plates with FastLane Cell Probe kit
or FastLane Cell Probe Multiplex kit (Qiagen). RNA
lysates were used in real-time one-step RT-qPCR reactions
performed on a Lightcycler 480 instrument (Roche). Gene
expression values were calculated using the comparative
delta delta Ct (-Ct) method, using housekeeper gene
Ct values and control-treated Ct for normalization as
described previously (20). FAM MGB Assay Probes
were obtained from Thermo Fisher Applied Biosystems:
KRAS (Hs00364284 g1), FOSL1 (Hs00759776 S1), 18S
rRNA (4352655), RAB5C (Hs00904926 g1), RNASEH1
(Hs 007702360 s1), KIF1A (Hs00987720 m1), KIF5C
(Hs00189672 m1), RAB5A (Hs00702360 s1) and RAB5B
(Hs00951468 M1). For dual-colour RT-qPCR reactions,
18S rRNA VIC (4318839) was used. For polymerase chain
reaction (PCR) analysis of ASO dose response treatment,
curves were plotted and data were analysed using non-
linear regression and curves were fitted using log (inhibitor)
versus response, variable slope (four parameters) equation
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using GraphPad Prism, curves were constrained between 0
and 1.
Protein isolation and western blotting
For western blot analysis, cells were washed three times
with ice-cold PBS and lysed in RIPA buffer (137 mM
NaCl, 20 mM Tris–HCl, pH 7.4 10% (v/v) glycerol, 1%
(v/v) Triton X-100 0.5% (w/v) sodium deoxycholate, 0.1%
(w/v) SDS) supplemented with PhosSTOP Phosphatase
Inhibitor Cocktail tablets (Roche), cOmplete Protease In-
hibitor Cocktail tablets (Roche) and Benzonase Endonu-
clease (Merck Millipore). Protein lysates were separated
on 4–12% Bis-Tris PAA gels (Invitrogen, ThermoFisher
Scientific) and transferred to nitrocellulose membranes.
Membranes were blocked in 5% w/v non-fat milk in
PBS plus 0.05% v/v Tween 20 (PBST) for an hour and
then probed with primary antibodies for 1 h at room
temperature or overnight at 4◦C. After washing, mem-
branes were incubated with secondary antibodies coupled
to horseradish peroxidase (HRP) for an hour at room tem-
perature, washed and proteins were detected using chemi-
luminescence with SuperSignal West Dura Extended Dura-
tion Substrate (Thermo Fisher). Primary antibodies used
for western blots were: KRas clone 2C1 (cat. C175665;
Lifespan Bioscience); vinculin clone hVIN-1 (cat. V9131;
Sigma); alpha-tubulin (DM1A, Cell Signalling Technol-
ogy); Lamin B1 (Cell signalling technologies), secondary
antibodies were sourced from Abcam (donkey anti-mouse-
HRP, donkey anti-rabbit-HRP).
Immunofluorescence
Cells were seeded onto 96-well glass-bottomed plates (Cel-
lvis) at 70% confluency. The following day cells were fixed
with 4% paraformaldehyde (PFA) (Affymetrix), washed
three times in PBS and then permeabilised with 0.2% Tri-
ton X-100 (Sigma). Cells were blocked in 2% w/v bovine
serum albumin (BSA) in PBS for 30 min before incuba-
tion with primary antibodies for 1 h at room temperature.
Plates were then washed in PBS before being incubated with
secondary antibodies for 1 h at room temperature in the
dark. After washing again in PBS, cells were imaged using
the Cell Voyager 7000 spinning disk confocal microscope
(Yokogawa) using the 60× water objective. Primary anti-
bodies used for immunofluorescence were: rabbit anti-ASO
(Ionis 13545) (14), mouse anti-LAMP-1 (BD Bioscience),
mouse anti-EEA-1 (BD Bioscience), Cis-Golgi (Abcam),
mouse anti-alpha tubulin (DM1A, Cell Signalling) and rat
anti-tubulin (Alexa Fluor® 647, Abcam). Secondary an-
tibodies used were donkey anti-rabbit (Alexa Fluor® 488)
and goat anti-mouse (Alexa Fluor® 555) sourced fromAb-
cam. Nuclei were stained with Hoechst (Thermo Fisher).
Image processing
All images were imported into Columbus analysis software
(Perkin Elmer) for quantifications of cell nuclei, cell area,
relative fluorescence (RFU) and co-localization. For analy-
ses, cells were identified using Hoechst, anti-ASO antibody
and tubulin stain, all boarder objects were removed and
only full cellular objects (filtered on size) were used for fur-
ther analysis. Cell area and morphology calculations were
calculated as mean per well across a minimum of 16 fields
per well. For co-localization analyses, preliminary valida-
tion of co-localization was first carried out in a small sam-
ple using FIJI (ImageJ) software (data not shown). Images
were imported into Columbus software from one z-plane
and correlation was calculated between the red and green
channels using Pearson’s Correlation Co-efficient analysis.
For RFU analysis, the quantification of AZD4785 fluores-
cence was determined in each cell and then corrected for the
background from untreated controls. Data were expressed
as mean per object (cell) per well, RFU was then divided
by average cell area for each cell line. Representative images
were compiled using FIJI (ImageJ) software from the orig-
inal TIFF images.
Mass spectrometry
NCI-H460 and LK2 cells were treated with 10 M
AZD4785. Cells were trypsinized, washed three times with
ice-cold PBS and counted, before lysing in RIPA buffer
as described previously. For cell fractionation experiments,
cells were processed using the ThermoFisher subcellular
fractionation kit (78840). Protein was quantified using BCA
assay (Pierce). Samples were analysed by UPLC-MS uti-
lizing a Waters Xevo TQ-XS (WBA0259) and an Acquity
UPLC system from Waters consisting of Sample Man-
ager (M16UFL953M),Acquity PDA (F17UPD457A), Col-
umn Oven (E17CMP703G) and Binary Solvent Manager
(E17BUR621G). Full mass spectrometry optimization and
methods can be found in Supplementary Figure S1.
siRNA screening assay
Custom-made siRNA library assay plates were reconsti-
tuted according to manufacturer’s instructions (Dharma-
con). NCI-H2030 cells were reverse transfected onto 384-
well tissue culture plates (Perkin Elmer) using RNAi max
(Invitrogen Thermofisher Scientific) at a final siRNA con-
centration of 20 nM. Cells were washed after 6 h and
fresh media added. After 72 h, cells were treated with vary-
ing concentrations of AZD4785, left for 48 h before be-
ing processed for RT-qPCR as described previously. KRAS
gene expression was normalized to housekeeping gene 18S
rRNA and shown relative to PBS control. Data were plotted
using GraphPad Prism Software; for determining siRNA
hits based on IC50, dose–response curves were plotted, and
data were analysed using non-linear regression and curves
were fit using log (inhibitor) versus response, variable slope
(four parameters) equation using GraphPad Prism, curves
were constrained between 0 and 1. For determining siRNA
hits based on maximum inhibition, dose–response curves
were plotted, and data were analysed using non-linear re-
gression. For siRNA validation experiments, siRNA On-
Target SMARTpool and single oligonucleotides were ob-
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tained from Dharmacon and reconstituted according to
manufacturer’s instructions.
Bioinformatic analysis
Oncoland Array Viewer was used to access TCGA patient
data and CCLE 37, CCLE 38 and Sanger 38 cell line data.
RNA Seq data were extracted and plotted using Graph Pad
Prism or R Studio.
RESULTS
Differential productive uptake of AZD4785, a cEt-
ASO, across tumour models in vitro
To investigate trafficking of cEt-ASOs within tumour cells,
we firstly determined the sensitivity of different cancer cell
lines from pancreatic, colon and lung tissue to cEt-ASO
treatment. To do this we used AZD4785, an example of
a next-generation ASO molecule with a phosphorothioate
backbone and constrained ethyl chemistry, which targets
the 3′UTR of KRAS mRNA (20).
The oncogene KRAS is reported to be required for the
initiation of cancer and is associated with poor prognosis
and poor patient survival (21,22). It is mutated in many
cancers, including colorectal, pancreatic and non-small cell
lung cancer (NSCLC) (23). Therefore, we constructed a cell
line panel from these three tumour types and then employed
KRASmRNAknockdown as ameasure of productive ASO
uptake capacity across these cancer cells. Cell lines were se-
lected to include both KRAS-wild-type and KRAS-mutant
genotypes to determine any differences oncogenic KRas ac-
tivity may have in mediating cEt-ASO uptake.
Cells were treated with ASO at doses ranging from 40
nM to 10 M, KRAS mRNA levels were measured by RT-
qPCR and IC50 and maximum inhibition at the highest
ASO dose calculated (Figure 1A and B). We observed a
range in response to ASO treatment across our cell panel
that was not tissue dependent (Figure 1A and B; Supple-
mentary Figure S2). Across the different cancer models,
four out of sixteen cell lines: colorectal carcinoma cell line
Colo-205, pancreatic cancer cell line MiaPaca-2 and lung
cancer cell linesNCI-H460 and PC9 had robust knockdown
of KRASmRNAwith a low IC50 (<600 nM) in response to
AZD4785 treatment. Six out of sixteen cell lines: colorec-
tal carcinoma cell line SW837, pancreatic cancer cell line
Panc 10.05 and lung cancer cell lines NCI-H1437, NCI-
H358, A549 and NCI-H2030 showed robust knockdown
of KRAS mRNA but with moderate IC50 (>600 nM, <2
M) and six out of sixteen cell lines: colorectal carcinoma
cell lines SW620 and HT-29, pancreatic cancer cell line
BxPC3 and lung cancer cell lines Calu-6, A427 and LK2
showed poor response to treatment withAZD4785, with lit-
tle to noKRASmRNAknockdown and high IC50 (>2M)
(Figure 1A and Supplementary Figure S2). Although there
was a continuum in free uptake capacity between cell lines,
for the purposes of comparison, cell lines were then classi-
fied according to the degree of KRAS knockdown; good,
moderate or poor with significant differences between the
poor and other uptake groups (Supplementary Table S1).
As mutant KRas has been reported to drive pathways of
trafficking within the cell, including macropinocytosis and
receptor-mediated endocytosis (24,25), we also assessed if
there was any association between KRAS mutation status
and cEt-ASO uptake. Surprisingly, there was no correlation
between KRAS mutation status and AZD4785-mediated
knockdown as both KRAS-mutant and wild-type geno-
types span both good and poor productive uptake groups
(Figure 1C). We next evaluated other key mutations associ-
ated with oncogenic and trafficking pathways; however, no
correlation with the degree of ASO uptake was found (Fig-
ure 1C).
The mechanism of action by which ASO AZD4785
down-regulates KRAS mRNA is through RNase H1-
mediated degradation. Thus, we assessed RNASEH1
mRNA levels to determine whether differences in expres-
sion of RNASEH1 could explain variation in productive
ASO uptake. Relative basal levels of RNASEH1 mRNA
across the cell panel did not correlate with the extent of
AZD4785-mediated knockdown observed (r = −0.1175),
suggesting that this was unlikely to be the mechanism driv-
ing the differences in productive uptake (Figure 1D and
Supplementary Figure S3). KRAS mRNA levels were also
not correlated (r = −0.1904) with the degree of KRAS
knockdown (Figure 1E and Supplementary Figure S4).
These data show that there are differences in productive
ASO uptake leading to varying degrees of target knock-
down across a diverse panel of tumour cell lines that are not
dependant on total RNASEH1 expression or basal levels of
ASO target.
cEt-ASOs enter cells in a dose-dependent manner with varied
intracellular distribution in good and poor productive uptake
models
AsASO-mediatedKRASmRNAknockdown varied across
the cell line panel, we wanted to investigate if this was de-
pendent on the amount of ASO internalized by the cell. To
do this, we focused on NSCLC cells that are enriched for
KRAS mutations occurring in ∼33% of lung adenocarci-
noma (26). Cellular internalization of ASO was determined
by immunofluorescence using an antibody that specifically
detects the phosphorothioate backbone of the antisense
drug (14,27). ASOaccumulatedwithin all the cells in a dose-
dependent manner (Figure 2A and Supplementary Figure
S5A), and even in cell lines with moderate or poor KRAS
knockdown we observed ASO staining within the cell (Fig-
ure 2B and C). Kinetics of intracellular ASO accumulation
was also evaluated and ASO-positive vesicles were detected
within cells 30min after treatment, indicating the AZD4785
ASO was internalized rapidly by endocytosis (Supplemen-
tary Figure S5B). ASO was detected within cells in vesicu-
lar structures at concentrations as low as 160 nM (Figure
2B and D), with ASO staining significantly increasing in
the cell at 10 M (Figure 2C and D). Interestingly, intra-
cellular ASO staining showed distinct patterns of distribu-
tion across the different cell lines. LK2 and A437, poor pro-
ductive uptake cells, had greater peripheral accumulation of
ASO close to the cell membrane. In contrast, within good
and moderate uptake cell lines there was greater ASO accu-
mulation in the perinuclear region (Figure 2C). Mass spec-
trometry has been shown as an effective label-free method
to measure intracellular exposure in cells of small molecule
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Figure 1. Differences in KRAS mRNA knockdown by cEt-ASO AZD4785 across a panel of cancer cell lines. (A and B) Colon, pancreatic and NSCLC
cancer cells were treated with a dose range of AZD4785 for 72 h and RT-qPCR used to assessKRASmRNA levels. Data were normalized to housekeeping
gene 18S rRNA and to PBS control. (A) IC50 and (B) maximum inhibition at 10 Mwere calculated for each cell line from a minimum of two experiments.
(C) Details of cell lines used in this study including key oncogenicmutations and productive uptake classification. (D andE) mRNA levels of (D)RNASEH1
or (E) KRAS mRNA were determined by RT-qPCR on lysates from untreated cells. Data were normalized to the housekeeping gene 18S rRNA and
expressed as mean delta Ct, then correlated with IC50 of inhibition of KRAS mRNA. Pearson’s correlation analysis was carried out on both RNASEH1
and KRAS with IC50 of KRAS knockdown and was found to be non-significant (-0.1175 and -0.1904, respectively).
drugs (28). We extended the approach to measure cellular
exposure of ASOs quantifying the amount of intact and la-
belled free intracellular AZD4785, focusing on NCI-H460
(IC50 < 150 nM) and LK2 (IC50 > 10M) as representative
good and poor productive uptake cell lines.Mass spectrom-
etry analysis showed there was no significant difference in
total cellular intact AZD4785 in NCI-H460 cells and LK2
cells indicating similar levels accumulate in the cell (Figure
2E). Depletion of free ASO from the cell culture media was
also quantified by mass spectrometry, with no significant
difference detected between NCI-H460 and LK2 cells (Fig-
ure 2F). The amount of intact free ASO detected in cell me-
dia was low (0.98 and 0.92M, respectively) most likely due
to ASO-protein binding in the media serum.
In summary, these data indicate that total levels of cEt-
ASO accumulation within the cell do not correlate with tar-
get knockdown and that comparable levels of intact cEt-
ASO are measured in total cell lysates from both good and
poor uptake cell lines. However, there are differences in lo-
calization of cEt-ASO between these cell lines suggesting
differences in intracellular pathways of trafficking.
Productive uptake and distribution of additional ASOs
To determine if the observation between ASO uptake and
intracellular distribution is similar across other molecules,
and not just specific to AZD4785, we expanded our study.
We selected two additional ASOs; Ionis 746275, another
KRAS targeting ASO that has both 2′MOE and cEt modifi-
cations (Figure 3A) and Ionis 549148, a non-targeting con-
trol ASO.We found that ASO-mediatedKRAS knockdown
by Ionis 746275 showed the same trends as AZD4785, with
the panel of cell lines separating into similar groups of good
(NCI-H460 and PC9), moderate (NCI-H1437, NCI-H358,
A549 andNCI-H2030) and poor uptake cells (Calu-6, A427
and LK2) (Figure 3B). We then looked at the non-targeting
ASO control, Ionis 549148 andRT-qPCR confirmed no tar-
get engagement with KRAS (Figure 3C).
We also compared intracellular distribution of these
ASOs: Ionis 746275 showed similar cellular distribution to
AZD4785, with perinuclear staining being observed in the
cell lines with goodASO uptake, andmore peripheral stain-
ing being observed in the poor uptake LK2 cell line (Fig-
ure 3D). The intracellular distribution patterns of the non-
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Figure 2. Quantification, intracellular distribution and accumulation of cEt-ASO across NSCLC cell lines. (A) Cell lines were seeded onto glass-bottomed
plates and treated with a dose range of AZD4785 or PBS. Cells were fixed at 72 h and nuclei stained with Hoechst, cytoskeleton with alpha-tubulin and
AZD4785 with an antibody that recognizes the phosphorothioate backbone of the antisense drug (anti-ASO antibody). Images were acquired and analysed
using Columbus software. Hoechst was used to define the cell nucleus and alpha-tubulin and anti-ASO antibody to define the cell cytoplasm for Columbus
analysis. Relative AZD4785 fluorescence (RFU) was quantified per object (cell) over 16 fields of view per well background corrected and normalized to
the calculated average cell area of each cell line. Data were analysed from a minimum of three experiments, error bars represent standard error of the mean
(SEM). (B and C) Representative images taken from NSCLC cells treated with (B) 160 nM or (C) 10 M of AZD4785 for 72 h. Images were acquired and
processed using FIJI (ImageJ) software; scale bar is 10 m. (D) Relative ASO fluorescence was quantified over 16 fields of view per well and normalized
to the average cell area of each cell line as previously described. Data were analysed from a minimum of three experiments, error bars represent SEM.
Results showed significant increase in immunofluorescence between 160 nM and 10 M dosing groups (t-test, P<0.001 (****)). (E) Mass spectrometry
was carried out on lysates from LK2 and NCI-H460 cells dosed with 10 M AZD4785 for 72 h to determine quantification of intact cellular ASO. Data
were analysed from three independent experiments, error bars represent SEM. (F) Mass spectrometry was carried out on cell culture media from LK2 and
NCI-H460 cell lines dosed with 10 MAZD4785 for 72 h. Data were analysed from three independent experiments, error bars represent SEM.
targeting control ASO, Ionis 549148, also showed the same
trend as observed with the other ASOs (Figure 3E). These
data show that the intracellular localization of ASOs is the
same regardless of target or sequence suggesting that ad-
vanced chemistry ASOs all traffic in the cell in similar ways
and probably through similar mechanisms.
Kinetics of ASO-mediatedKRAS knockdown varies between
NSCLC cell lines
Although internalization of ASO occurs rapidly, within 30
min of incubation (Supplementary Figure S5B), maximum
target knockdown occurs later between 24 and 72 h post ini-
tial dosing depending upon the cell line. Therefore, to fur-
ther explore the kinetics of ASO intracellular trafficking, we
carried out pulse-chase experiments. Cells were treated with
various doses of ASO for fixed exposure times, before wash-
ing and then incubating in fresh medium until processing at
72 h after the start of the treatment (Figure 4A).
A 30-min and 4-h pulse with ASO did not cause a sig-
nificant reduction in KRAS mRNA expression in any of
the cell lines at any concentration, indicating that longer
exposure to the treatment is needed for target knockdown
(Figure 4B and C). Following 24 and 48 h ASO exposure,
levels of KRAS knockdown varied across cell lines. As a
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Figure 3. Uptake and intracellular distribution of additional ASO molecules across NSCLC cell lines (A) AZD4785 and Ionis 746275-binding sites on
KRAS mRNA. (B and C) NSCLC cell lines were treated with a dose range of (B) Ionis 746275 or (C) Ionis 549148 for 72 h and RT-qPCR used to assess
KRASmRNA levels. Data were normalized to housekeeping gene 18S rRNA and to PBS control. Data shown are representative of multiple experiments.
(D and E) Cell lines were seeded onto glass-bottomed plates and treated with 10 M of (D) Ionis 746275 or (E) Ionis 549148. Cells were fixed at 72 h and
nuclei stained with Hoechst, cytoskeleton with alpha-tubulin and ASO with anti-ASO antibody, and images were processed using FIJI (ImageJ) software;
scale bar is 10 m.
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A
B
C
D
E
Figure 4. Kinetics of knockdown by cEt-ASO AZD4785. (A) Schematic showing the experimental design of this study. NSCLC cell lines were treated with
a dose range of AZD4785 and washed after various time points before processing at 72 h. (B–E) Relative expression of KRAS mRNA by RT-qPCR after
cells were exposed to a dose range of AZD4785 for (B) 30 min, (C) 4 h, (D) 24 h, (E) 48 h before samples were collected at 72 h after the start of initial
dosing. Data were normalized to the housekeeping gene 18S rRNA and shown relative to PBS control. Data represent the mean and range from aminimum
of three independent experiments and error bars represent SEM. A one-way analysis of variance (ANOVA) was performed to assess significance, P<0.05
(*), P<0.01 (**) and P<0.001 (***). Tukey’s post-hoc test was carried out for multiple comparisons between cell lines (Supplementary Table S2).
group the good productive uptake cell lines, NCI-H460
and PC9, showed KRAS knockdown with concentrations
of AZD4785 as low as 600 and 160 nM; however, as ex-
pected, we do not observe this in poor cell lines A427 and
LK2 (Figure 4D andE; Supplementary Table S2). At higher
doses of AZD4785, we also see differences between the cell
line groups; at 24-h exposure to 2.5M, there are significant
differences between cell lines in the good uptake group com-
pared to the moderate and poor uptake cell lines (Figure
4Dand SupplementaryTable S2). Together, these data high-
light fundamental differences in the kinetics of productive
uptake of ASOs across cell lines suggesting that the path-
ways of trafficking differ between these cell lines.
Poor productive uptake cell lines show stronger cEt-ASOs
co-localization with the late endosome/lysosome marker
LAMP-1
Previous work has established thatASOs enter cells through
endocytic processes (13,14). Once internalized, they are
trafficked to the early endosome and may have various fates
including; being recycled back to themembrane through re-
cycling endosomes, trafficking to the trans-Golgi network
or transported to the late endosome to be delivered to
the lysosome for degradation or into multivesicular bodies
(MVBs) to be delivered out of the cell by exocytosis (29).
Therefore, cell lines used in this panel were profiled to assess
cell size and also the distribution of key cellular organelles
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involved in intracellular trafficking (Supplementary Figure
S6). Early endosome antigen 1 (EEA1) was used to im-
age early endosome localization, and EEA1 positive vesi-
cles had distribution close to the perinuclear region as well
as the cytoplasm across all cell lines (Supplementary Fig-
ure S7). Imaging of the late endosome and lysosomemarker
LAMP-1 showed distinct variations in cellular distribution
across the cell lines (Figure 5). In the good productive up-
take cell line, panel NCI-H460 and PC9 and also the mod-
erate cell lines NCI-H1437, NCI-H358 and A549, LAMP-1
staining was scattered throughout the cytoplasm. However,
in the NCI-H2030 and Calu-6 cell lines, LAMP-1 staining
was shown to have a more endoplasmic reticulum-like dis-
tribution. Interestingly, in A427 and LK2 cell lines, which
were shown to have the poorest productive uptake with no
ASO-mediatedKRAS knockdown, LAMP-1 staining local-
ized to the cell protrusions and clustered close to the cell
membrane (Figure 5).
A series of co-localization experiments were set up to
determine if there was any correlation of ASO staining
with late endosome/lysosome markers. Again, we used a
pulse-chase experiment design, where cell lines were treated
with AZD4785 and washed at various time points before
being fixed and stained for LAMP-1 and ASO at 72 h
(Figure 6A and B). After 30-min exposure to 10 M of
AZD4785, co-localization betweenLAMP-1 andAZD4785
occurred in the poor uptake cell line cohort LK2, A427
and Calu-6 (Pearson’s correlation coefficient, PCC > 0.4).
There was less correlation in the moderate cell lines NCI-
H2030, NCI-H358 and A549 (PCC < 0.4, >0.2) and there
was no correlation in co-localization in moderate cell line
NCI-H1437 and good uptake cell lines NCI-H460 and PC9
(PCC< 0.09) (Figure 6C). After 24-h exposure to 10 Mof
AZD4785, co-localization betweenLAMP-1 andAZD4785
increased across all cell lines, correlation was strong (PCC
> 0.5) in the poor uptake cell line cohort (LK2, A427 and
Calu-6). There was increased correlation in NCI-H2030,
NCI-H358, A549 and PC9 cell lines (PCC < 0.5, >0.3);
however, there was weaker correlation observed in the NCI-
H460 and NCI-H1437 cell lines (PCC < 0.2) (Figure 6C).
We observed strong co-localization between ASO and
LAMP-1 after cells were treated with 10 and 2.5 M of
ASO across all time points in poor uptake cell lines, sug-
gesting rapid trafficking at higher doses of AZD4785 (Sup-
plementary Figure S8). However, even treatment with lower
concentrations of ASO lead to strong co-localization be-
tween LAMP-1 and ASO across the poor uptake cell lines
at the later time points (24- and 48-h exposure) suggest-
ing co-localization may also be time and dose dependent
at lower concentrations in these cell lines (Supplementary
Figure S8).
To determine how rapidly co-localization with LAMP-
1 occurred, we also carried out a fixed time-course ex-
periment in NCI-H460 and LK2 cells quantifying co-
localization of ASO with LAMP-1 at 4 and 72 h follow-
ing dosing (Supplementary Figure S9). Four hours follow-
ing dosing with AZD4785, LK2 cells had stronger corre-
lation of ASO and LAMP-1 co-localization at higher con-
centrations, compared to NCI-H460 (Supplementary Fig-
ure S9AandC).After 72 h treatment at concentrations from
40 nMAZD4785 and higher, we saw significantly higher co-
localization of ASO with LAMP-1 in LK2 cells that we did
not see in NCI-H460 cells (Supplementary Figure S9B and
D). Thus, these data suggest that in NSCLC cell lines that
have poor ASO-mediated KRAS knockdown, more ASO
is being trafficked on the late endosome-lysosome pathway
for degradation or exocytosis, which may be an important
mechanism that prevents productive uptake of ASOs.
We also observed that there were some differences in gen-
eral levels of AZD4785 detectable by immunofluorescence
across cell lines following 24-h exposure, especially between
NCI-H460, which has the best productive uptake and LK2,
which has the worst (Figures 6D). To examine this more
closely,mass spectrometry analyseswere performed on total
cell lysates from NCI-H460 and LK2 exposed to AZD4785
for 30 min or 24 h before being processed at 72 h (Figure
4A). A 30-min exposure to treatment resulted in ASO levels
that were outside the low range in both cell lines (data not
shown); however, after 24-h exposure, we detected higher
levels of intact ASO within LK2 cells compared to NCI-
H460 cells (Figure 6E). RobustKRAS knockdown occurs in
NCI-H460 cells following 24 h exposure (Figure 4D); there-
fore the lower levels detected in these cells by mass spec-
trometry following the same exposure to AZD4785 could
be due to degradation of cytoplasmic ASO or exocytosis
from the cell following its activity.
Kinesin-1 and Kinesin-3 Motor proteins are associated with
ASO trafficking in poor productive uptake cells
To identify factors that may contribute to regulating dif-
ferences observed in intracellular trafficking and lysoso-
mal distribution of ASOs across models, a bioinformatics
approach was utilized. Analysis of gene signatures associ-
ated with cellular trafficking was assessed for differential
expression across the cell panel. Investigation of the ki-
nesin and dynein gene families showed that genes (KIF1A
and KIF5C) encoding components of the kinesin motor
protein complexes, kinesin-1 and kinesin-3, were differen-
tially regulated in poor productive uptake cell lines (Fig-
ure 7A and Supplementary Figure S10). RT-qPCR con-
firmed KIF1A mRNA levels were up-regulated in Calu-6,
A427 and LK2 cells (Figure 7B), and KIF5C mRNA lev-
els were up-regulated in A427 and LK2 cells (Figure 7C).
These data show high levels of KIF1A and KIF5C expres-
sion correlate with poor productive ASO uptake in NSCLC
cells, highlighting a potential novel pathway regulating non-
productive ASO cellular trafficking.
cEt-ASO accumulates in the nucleus of cells with productive
uptake
To further address where ASOs are trafficked within cells,
additional mass spectrometry experiments were carried out
using representative good (NCI-H460) and poor (LK2) cell
lines dosed with 10 M AZD4785 and fractionating into
cytoplasmic, membrane bound and nuclear components.
Mass spectrometry analysis showed that there were no sig-
nificant differences between the cell lines for the cytoplasmic
andmembrane fractions (Figure 8A and B). However, anal-
ysis of the nuclear fraction showed that there were signifi-
cantly higher levels of ASO inNCI-H460 cells, compared to
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Figure 5. Lysosomal distribution is varied across the panel of cell lines. Confocal z-stack images of untreated NSCLC cells were acquired to visualize
LAMP-1 across cell lines. Nuclei were stained with Hoechst, cytoskeleton with alpha-tubulin and late endosomes/lysosomes with LAMP-1. Images were
processed using FIJI (ImageJ software) and shown as a maximum projection of the z-stack images. Lysosome distribution indicated on merged image by
white arrows, zoom shows enlarged image section, scale bar 10 m.
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Figure 6. Differences in cEt-ASO trafficking to the lysosome across cell lines. Confocal z-stack images of NSCLC cells to visualize AZD4785 and LAMP-1
co-localization within the cell were taken 72 h after AZD4785 exposure (10 M) for (A) 30 min and (B) 24 h, zoom shows 10× fold enlarged image section;
scale bar 10 m. (C) For co-localization quantification, confocal images were also taken on one z-plane 72 h after AZD4785 treatment. Co-localization
between ASO and LAMP-1 in NSCLC cell lines was calculated by Pearson’s correlation coefficient (PCC) after 30 min or 24 h of AZD4785 exposure, on 16
fields of view per well, from a minimum of three independent experiments, error bars represent SEM. (D) Quantification of AZD4785 immunofluorescence
in NSCLC cell lines after 24-h exposure to 10 Mof AZD4785, on 16 fields of view per well, from a minimum of three independent experiments, error bars
represent SEM. (E) Mass spectrometry was carried out on lysates from NCI-H460 and LK2 cells to quantify intact AZD4785 oligonucleotides after 24-h
exposure to 10 M AZD4785, error bars represent standard deviation (SD). A one-way ANOVA was carried out to assess significance between groups,
P<0.05 (*).
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Figure 7. Expression of kinesin motor proteins across the cell panel. (A) Expression ofKIF1A andKIF5C analysed using OmicSoft ArraySuite, OncoLand
software, using RNAseq expression data for available cell lines exported from the Sanger 38 database. Log2 (FPKM+0.1) values were plotted as a heat
map. (B and C) mRNA levels of KIF1A and KIF5C were determined by RT-qPCR on untreated cell lines, data were normalized to the housekeeping gene
18S rRNA and shown relative to A549 cells, individual values from a minimum of three independent experiments are shown. Error bars represent the mean
and the range.
A B C
Figure 8. Detection of intact ASO from cellular fractions. Mass spectrometry was carried out on cellular fractions to quantify intact ASO after 72-h
exposure to 10MAZD4785. (A andB) There were no significant differences betweenASO in cytoplasmic andmembrane fractions from three independent
experiments (error represents SEM). (C) There was a significant difference between intact ASO in the nuclear fraction between the two cell lines from three
independent experiments, (error bars represent SEM, a one-way ANOVA was carried out to assess significance between groups, P<0.05 (*)).
LK2 cells (Figure 8C and Supplementary Figure S11) sug-
gesting in good uptake cell lines ASO traffics to the nucleus.
Productive ASO uptake is modulated by Rab5C
To elucidate additional pathways and functional factors
that could be responsible for the variations observed in pro-
ductive uptake and in cellular distribution and trafficking
of ASOs, we carried out a gene silencing (siRNA) screen.
As trafficking of ASOs had previously been described as
an endocytic process (9–11), the screen was carried out us-
ing a library of 210 genes involved in membrane trafficking.
Genes involved in metabolic processes and translation have
also been linked to the productive uptake of ASOs; there-
fore, we included a selection of genes involved in regulating
metabolic pathways (30–32). We used a siRNA screening
approach, as siRNAact to silencemRNAvia incorporation
with RNA-induced silencing complex (RISC) and not an
RNase H-dependent mechanism, so, therefore, would not
interfere with AZD4785 antisense oligonucleotide activity.
NCI-H2030 cells, a moderate uptake line, were selected to
be used in this screen as we reasoned this would enable the
detection of factors that either increase or decrease produc-
tive ASO uptake. Cells were transfected with siRNA and
then treated with a dose response of AZD4785 to determine
the effect on ASO-mediated KRAS down-regulation. Data
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were analysed by looking for changes in the IC50 (Figure
9A) and maximum inhibition ofKRASmRNA (Figure 9C)
following ASO treatment. A number of genes had an im-
pact on ASO-mediated KRAS knockdown when silenced.
The screening hits which decreased ASO IC50 were ranked
and the highest ranking genes were taken forward for fur-
ther validations; the RAB5 isoform, RAB5C, was the top-
ranking hit from the screen (Figure 9B and D).
Knockdown of Rab-GTPase RAB5C using a siRNA
pool prior to dosing with AZD4785 caused a shift in the
IC50 of KRAS mRNA knockdown from 870 nM to 8 M,
indicating this is required for the productive trafficking of
the drug (Figure 10A). The importance of RAB5C in the
productive uptake of ASOs was also confirmed using indi-
vidual siRNA (Supplementary Figures S12 and S13). West-
ern blotting also confirmed that siRAB5C impaired ASO-
mediated knockdown of KRas protein compared to the
control siRNA (Figure 10B).We assessedwhether there was
any association between degree of ASO uptake (as mea-
sured byKRAS knockdown) andRAB5C expression across
our panel of NSCLC cell lines; however there was no corre-
lation (Figure 10C). RAB5 has three isoforms: A, B and C,
and data fromour siRNA screen also identifiedRAB5A and
RAB5B as important in ASO productive uptake (Figure 9).
However, RAB5C appears most important in NCI-H2030
cells. We examined expression of the RAB5 isoforms across
the panel of cell lines by RT-qPCR and found that in NCI-
H2030 cells the RAB5C isoform was more highly expressed
thanRAB5A andRAB5B (Figure 10D). This trend was also
observed in NCI-H460, NCI-H1437, A549 and Calu-6 cells
(Figure 10D) and analysis of data from the Cancer Genome
Atlas also confirmed this trend across patient samples (Sup-
plementary Figure S14). However, PC9, NCI-H358, A427
and LK2 cells showed similar expression levels of RAB5B
to RAB5C (Figure 10D). Next, we wanted to confirm if
RAB5C depletion impacted ASO-mediated KRAS knock-
down across other moderate uptake cell lines. We found
that siRAB5C affectedKRAS knockdown inA549 cells, an-
other moderate uptake cell line (Figure 10E) although no
impact was seen in NCI-H358 cells (data not shown), per-
haps due to high relative co-expression of RAB5B (Figure
10D). Taken together these data suggest that Rab5 proteins,
in particular Rab5C, are important in regulating productive
ASO trafficking.
DISCUSSION
Advances in ASO chemistry have enabled the generation
of therapeutic ASOs with drug-like properties including
AZD4785, a potent and selective KRAS ASO that is be-
ing developed to treat KRas-dependent tumours (20). De-
spite progress in the field of ASO trafficking and delivery,
productive uptake of advanced chemistry ASOs is a com-
plex process that is not yet fully understood (17,33). Un-
derstanding the mechanisms of ASO trafficking in relevant
tumour models could enable insights into medicinal chem-
istry, delivery and combination approaches to improveASO
productive uptake, as well as identifying patient selection
strategies to ascertain those most likely to benefit from an-
tisense therapeutics such as AZD4785.
ASO productive uptake varies within tumour models but does
not correlate with quantity of internalized ASO
We examined the mechanisms of ASO trafficking across a
tumour cell line panel to provide an overview of uptake
and intracellular trafficking across clinically relevant mod-
els. Here, we report in colon, pancreatic and NSCLC cell
lines, the IC50 of target knockdown with AZD4785 (with
unformulated delivery) differed dramatically, ranging from
cell lines that had a robust knockdown, to those that had
minimal or no knockdown of KRAS mRNA. These differ-
ences were observed across cell lines and did not correlate
with basal expression of RNASEH1 or KRAS mRNA, in-
dicating that pathways of ASO trafficking or mechanisms
of endosomal release must be differentially regulated across
cell lines. Immunofluorescence and mass spectrometry both
confirmed that similar levels of ASO enter the cell, regard-
less of the degree of target knockdown, highlighting the im-
portance of ASO intracellular trafficking.
Rab5C plays a role in productive ASO trafficking
It is known that ASOs enter cells through endocytic events
and are delivered to the early endosome (9). The early endo-
some (also referred to as the sorting endosome) plays a cru-
cial role in endocytosis as it determines the route of cargo
(34). Material can be transported from early to late en-
dosomes through transport carriers or via early endosome
remodelling to late endosomes (34). Rab5 is a marker of
early endosomes and is known to be important in promot-
ing endosome fusion in endocytosis, mediated by its gua-
nine nucleotide exchange factor (GEF) that acts a molecu-
lar switch converting Rab5-GDP to Rab5-GTP (35). Late
endosomes are formed by conversion of mature early endo-
somes, marked by the loss of Rab5 (early endosome) and ac-
quisition of Rab7 (late endosome) (34). Data from our 210-
gene siRNA screening work identified Rab5C as important
in ASO productive uptake. Rab5C has also recently been
reported to be important in the productive trafficking path-
way of 2′MOE ASOs in engineered Stabilin-expressing cell
lines, also confirming the findings from our siRNA screen
(36). Our study suggests this role is also conserved in can-
cer cell lines and with cEt-ASOs. We demonstrate that loss
ofRAB5CmRNA interferes with the productive trafficking
pathway of ASO, as we see a reduction in ASO-mediated
KRAS down-regulation. This indicates that Rab5C may
play an important role in mediatingmechanisms of ASO es-
cape from the early endosome, or ASO escape during early
endosome maturation. Whilst we did not see any correla-
tion between RAB5C expression and degree of ASO up-
take (Figure 10C), differences in uptake may not be driven
by overall Rab5C expression, but rather by functional re-
cruitment that can be regulated by other factors. Rab5 has
three distinct isoforms that share roughly 90% sequence ho-
mology (37,38). Preliminary screening in NCI-H2030 cells
suggested a role for all three isoforms in the productive up-
take of ASOs; however, RAB5C knockdown had the most
robust impact on ASO productive uptake across moderate
uptake cells H2030 and A549, likely due to its higher rel-
ative expression. Furthermore, analysis across the NSCLC
cell panel and TCGA patient data also highlighted differ-
ential expression of RAB5 isoforms with RAB5C being the
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Figure 9. siRNA screen to identify factors that impact ASO productive trafficking. NCI-H2030 cell lines were transfected with siGenome pools and treated
with a dose range of AZD4785, before RT-qPCR was carried out to determine KRAS mRNA levels. Data were normalized to housekeeping gene 18S
rRNA and PBS control. IC50 data were plotted and a 3-fold threshold cut off was applied to determine genes of interest compared to the non-targeting
and RISC-free controls. (A and B) Genes that significantly change the IC50 of AZD4785 productive uptake. Data shown represent the mean IC50 and
range of biological duplicates from two independent screening experiments. (C andD) Maximum % inhibition of KRAS mRNA following treatment with
AZD4785. Data represent the mean and range of biological duplicates from two independent screening experiments, a one-way ANOVA was used to
calculate significance compared to the controls, indicated by the asterisk (* P<0.05, ** P<0.01).
most predominantly expressed. The Rab5C isoforms have
also been shown to have distinct functions in EGFR degra-
dation and trafficking (39,40) and Rab5C has also been re-
ported to be associated with enhanced cellular motility and
growth-factor activation of RAC1 (37). Therefore, it is also
possible that there is an independent role for Rab5C in ASO
trafficking and delivery distinct from Rab5A and Rab5B.
Expanding the study across more cell lines would be inter-
esting in determining the role of Rab5C and other isoforms
in ASO productive trafficking outside of NSCLC.
ASO traffics rapidly to the late endosome and lysosome in
poor productive uptake cell lines and to the nucleus in cell with
good productive uptake
It is known that once cargo is contained within the late
endosome a number of factors can affect its fate within
the cell, such as acidification of the vesicle compartments
required for degradation in the lysosome. Besides deliver-
ing cargo to the lysosome, late endosomes and lysosomes
can also fuse with the plasma membrane delivering mate-
rial out of the cell, known to be regulated by Rab27A (41–
43). Across our cell line panel, we observed that traffick-
ing of ASO to the late endosome and lysosome was more
rapid in cells with poor productive uptake, suggesting that
ASO may be rapidly degraded in these cell lines or bypass
routes leading to productive uptake. We also observed a
greater frequency of larger vesicles clustering in the poor
productive uptake cell lines compared to the good uptake
cell lines and these larger clusters of AZD4785 appeared to
be MVBs (data not shown). Interestingly, in this study, cell
lines that had poor ASO-mediated KRAS mRNA knock-
down also had varied distribution of internalized ASO, lo-
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Figure 10. RAB5C regulates ASO productive uptake in NSCLC. (A) Data showing IC50 dose–response curves for KRAS mRNA knockdown in H2030
cells transfected with siRNA targeting RNASEH1, RAB5C or negative controls for 72 h and then treated with AZD4785 for 48 h. Data were normalized
to housekeeping gene 18S rRNA and PBS control. Results were expressed from the mean of biological duplicates from each experimental run and then
averaged across two independent experiments. Error bars represent SEM. (B) Western blot analysis of KRas and vinculin levels in lysates from H2030 cells
transfected for 72 h with siRNA On-Target SMARTpools for RAB5C, RNASEH1 or non-targeting control (siNTC) before treating with AZD4785 for 48
h. Red box highlights differences in KRas proteins levels between control and siRAB5C transfected cells. (C) RT-qPCR was carried out on untreated cells
to determine expression levels of RAB5C across the cell panel. Data were normalized to 18S rRNA control and shown relative to H2030 cells. Data shown
represent the mean and SEM from a minimum of three experiments. (D) RT-qPCR was carried out on untreated cells to determine expression levels of
RAB5 isoforms across the cell panel. Data were normalized to 18S rRNA control and shown relative to RAB5C. Data shown represent the mean and SD
from a minimum of two experiments. (E) Data showing IC50 dose–response curves for KRAS mRNA knockdown in A549 cells transfected with siRNA
targeting RNASEH1, RAB5C or siNTC for 72 h and then treated with AZD4785 for 48 h. Data were normalized to housekeeping gene 18S rRNA and
PBS control. Results were expressed from the mean of biological duplicates from an experimental run, error bars represent the range.
calizing to the cell periphery. Our analysis identified differ-
ential expression of KIF1A and KIF5C encoding compo-
nents of the kinesinmotor proteins: kinesin-1 and kinesin-3.
These motor proteins have previously been reported to par-
ticipate in peripheral lysosomal trafficking along the micro-
tubules (44). This suggests a mechanism by which ASOs are
rapidly transported to the cell periphery by kinesin-1 and -3
in the cells with poor ASO uptake, leading to either degra-
dation or exocytosis (Figure 11). It is well established that
MVBs can fuse with the plasma membrane, resulting in the
release of extracellular vesicles (45,46). Therefore, it is pos-
sible that the peripheral distribution of ASO is indicative of
a functional pathway of exocytosis, whereby the MVBs are
secreting intraluminal vesicles containing ASO out of the
cell as exosomes. Further work investigating pathways of
exocytosis and exosome secretion would be a key to under-
standing the non-productive trafficking pathways of ASOs
within the cell.
In this work, we demonstrate a novel method for detect-
ing intact ASO within the cell, culture media and cellular
fractions. Our findings suggest that in cells with good ASO
uptake we see an increase in ASO accumulation in the nu-
cleus that is significantly higher compared to poor uptake
cells. Comparison of total cell lysates showed comparable
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Figure 11. Schematic to show the proposed mechanism of ASO productive and non-productive trafficking in the cell. ASO is trafficked to the early
endosome where it may be recycled back to the membrane or undergo endosomal escape mediated by Rab5C. The early endosome can fuse with the late
endosome or multivesicular body and transport cargo, likely through motor proteins kinesin-1 and-3, either to the lysosome for degradation or to the cell
periphery where it fuses with the plasma membrane and is secreted out of the cell via extracellular vesicles.
quantities of ASO between different cell lines, again con-
firming the differences in trafficking pathways between the
good and poor productive uptake models.
CONCLUSION
This study focused on cEt-modified ASOs, and is the first
to investigate ASO uptake across a panel of clinically rele-
vant cell lines, to characterize differences in productive up-
take mechanisms. We have shown a comprehensive anal-
ysis of ASO driven target knockdown, kinetics and traf-
ficking. In addition we have identified a possible mecha-
nism through kinesin motor proteins that may be crucial
for non-productive ASO trafficking to late endosome and
lysosomes. Furthermore, we have presented novel insights
into Rab5C-dependent trafficking of ASOs, which may de-
termine the fate of the antisense oligonucleotide within the
cell (Figure 11).
A number of recent studies have demonstrated mech-
anisms of 2′MOE ASO trafficking within the cell, con-
centrating on escape/release into the cellular cytoplasm
(18,19). However, to date there have been no studies char-
acterizing trafficking of therapeutic ASOs containing 2′-
4′ constrained ethyl advanced chemistry modifications. We
broadened our study beyond AZD4785 and characterized
ASO uptake and intracellular distribution using two other
ASO molecules including an ASO that contained both cEt
and 2′MOE modifications. While our data suggest that
mechanisms of ASO uptake and trafficking may be con-
served across ASOs with different sequences and chemistry,
further investigation across a broad range of ASOs includ-
ing those with different mechanism of action would be in-
teresting to determine if uptake mechanisms are conserved.
Whilst this study explores productive uptake of ASO
across several clinically relevant cancer models, further
work across other tumours types, in vivo models (e.g. in
cell-derived and patient-derived xenograft (PDX) models),
as well as normal cells and tissues, would help under-
stand if Rab5C function in productive uptake is univer-
sally conserved. Finally, future work should explore exact
molecular mechanisms engaged by kinesin proteins in non-
productive uptake and Rab5C in facilitating productive up-
take ofASOs. Continuedwork to establishmechanisms that
may mediate ASO escape from the endosome into the cyto-
plasm or factors that may impair this will help identify pa-
tient selection strategies or strategies to enhance the phar-
macological effects of antisense drugs.
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